The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Type I interferons in infectious disease
Open accessAbstract
Type I interferons (IFNs) have diverse effects on innate and adaptive immune cells during infection with viruses, bacteria, parasites and fungi, directly and/or indirectly through the induction of other mediators. Type I IFNs are important for host defence against viruses. However, recently, they have been shown to cause immunopathology in some acute viral infections, such as influenza virus infection. Conversely, they can lead to immunosuppression during chronic viral infections, such as lymphocytic choriomeningitis virus infection. During bacterial infections, low levels of type I IFNs may be required at an early stage, to initiate cell-mediated immune responses. High concentrations of type I IFNs may block B cell responses or lead to the production of immunosuppressive molecules, and such concentrations also reduce the responsiveness of macrophages to activation by IFNγ, as has been shown for infections with Listeria monocytogenes and Mycobacterium tuberculosis. Recent studies in experimental models of tuberculosis have demonstrated that prostaglandin E2 and interleukin-1 inhibit type I IFN expression and its downstream effects, demonstrating that a cross-regulatory network of cytokines operates during infectious diseases to provide protection with minimum damage to the host.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“If type I IFNs are present early and properly localized to sites of infection, they can effectively limit viral propagation, as type I IFNs are responsible for optimal activation of macrophages, antigen presentation by DCs, and enhanced anti-viral effector T cell responses106.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,871
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J. V., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,533
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2013) · Nature reviews. Immunology · doi:10.1038/nri3581 · Cited by 3,442
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., Ó’hUigín, C., Kidd, J. R., Kídd, K. K., Khakoo, S. I., Alexander, G., et al. (2009) · Nature · doi:10.1038/nature08463 · Cited by 2,147
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis
Berry, M. P. R., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A. A., Oni, T., Wilkinson, K. A., Banchereau, R., Skinner, J., Wilkinson, R. J., et al. (2010) · Nature · doi:10.1038/nature09247 · Cited by 1,898
Self-citationInterferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,845
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M. V., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M. F., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,829
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,004
Innate immunological pathways in COVID-19 pathogenesis
Paludan, S. R., & Mogensen, T. H. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm5505 · Cited by 188
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 192
Type-I-interferon-responsive microglia shape cortical development and behavior
Escoubas, C. C., Dorman, L. C., Nguyen, P. T., Lagares-Linares, C., Nakajo, H., Anderson, S. R., Barron, J. J., Wade, S. D., Cuevas, B., Vainchtein, I. D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.020 · Cited by 179
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
Yang, H., Ma, Y., Chen, G., Zhou, H., Yamazaki, T., Klein, C., Pietrocola, F., Vacchelli, E., Souquère, S., Sauvat, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149673 · Cited by 188
Paijo, J., Döring, M., Spanier, J., Grabski, E., Nooruzzaman, M., Schmidt, T., Witte, G., Messerle, M., Hornung, V., Kaever, V., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005546 · Cited by 194
Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra
Ji, D. X., Yamashiro, L. H., Chen, K. J., Mukaida, N., Kramnik, I., Darwin, K. H., & Vance, R. E. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0578-3 · Cited by 183
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
Penn‐Nicholson, A., Mbandi, S. K., Thompson, E. G., Mendelsohn, S. C., Suliman, S., Chegou, N. N., Malherbe, S. T., Darboe, F., Erasmus, M., Hanekom, W. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65043-8 · Cited by 179
The link between circulating follicular helper T cells and autoimmunity
Walker, L. S. K. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00693-5 · Cited by 182
Regulated cell death and adaptive stress responses
Galluzzi, L., Bravo-San Pedro, J. M., Kepp, O., & Kroemer, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2209-y · Cited by 177
Ali, S., Mann‐Nüttel, R., Schulze, A., Richter, L., Alferink, J., & Scheu, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00778 · Cited by 176
STING-dependent translation inhibition restricts RNA virus replication
Franz, K. M., Neidermyer, W. J., Tan, Y., Whelan, S. P. J., & Kagan, J. C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716937115 · Cited by 183
KDM5 histone demethylases repress immune response via suppression of STING
Wu, L., Cao, J. P., Cai, W. L., Lang, S. M., Horton, J. R., Jansen, D. J., Liu, Z. Z., Chen, J. F.-Y., Zhang, M., Mott, B. T., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2006134 · Cited by 182
Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation
Rialdi, A., Campisi, L., Zhao, N., Lagda, A. C., Pietzsch, C. A., Ho, J., Martínez‐Gil, L., Fenouil, R., Chen, X., Edwards, M. R., et al. (2016) · Science · doi:10.1126/science.aad7993 · Cited by 177
TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection
de Marcken, M., Dhaliwal, K., Danielsen, A. C., Gautron, A. S., & Dominguez‐Villar, M. (2019) · Science Signaling · doi:10.1126/scisignal.aaw1347 · Cited by 184
Wiens, K. E., & Ernst, J. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005809 · Cited by 176
Kim, J. K., Kim, Y. S., Lee, H., Jin, H. S., Neupane, C., Kim, S., Lee, S., Min, J., Sasai, M., Jeong, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06487-5 · Cited by 175
Mapping and role of T cell response in SARS-CoV-2–infected mice
Zhuang, Z., Lai, X., Sun, J., Chen, Z., Zhang, Z., Dai, J., Liu, D., Li, Y., Li, F., Wang, Y., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202187 · Cited by 175
Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection
Murira, A., & Lamarre, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00609 · Cited by 176
Interferon-Stimulated Genes as Enhancers of Antiviral Innate Immune Signaling
Crosse, K. M., Monson, E. A., Beard, M. R., & Helbig, K. J. (2017) · Journal of Innate Immunity · doi:10.1159/000484258 · Cited by 169
C-Type Lectin Receptors in Antiviral Immunity and Viral Escape
Bermejo‐Jambrina, M., Eder, J., Helgers, L. C., Hertoghs, N., Nijmeijer, B. M., Stunnenberg, M., & Geijtenbeek, T. B. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00590 · Cited by 184
Nakamori, Y., Park, E. J., & Shimaoka, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624279 · Cited by 176
Kramnik, I., & Beamer, G. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0538-9 · Cited by 169
Type I interferon pathway in CNS homeostasis and neurological disorders
Blank, T., & Prinz, M. (2017) · Glia · doi:10.1002/glia.23154 · Cited by 172
No Love Lost Between Viruses and Interferons
Fensterl, V., Chattopadhyay, S., & Sen, G. C. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055249 · Cited by 167
Macrophage: Key player in the pathogenesis of autoimmune diseases
Yang, S. C., Zhao, M., & Jia, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1080310 · Cited by 165
Shi, X., Zhou, H., Wei, J., Mo, W., Li, Q., & Lv, X. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102553 · Cited by 166
Type I Interferons as Regulators of Lung Inflammation
Makris, S., Paulsen, M. T., & Johansson, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00259 · Cited by 166
Interferon Lambda: Modulating Immunity in Infectious Diseases
Syedbasha, M., & Egli, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00119 · Cited by 170
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon
Mylonas, A., & Conrad, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02746 · Cited by 161
T cell engagement of cross-presenting microglia protects the brain from a nasal virus infection
Moseman, E. A., Blanchard, A. C., Nayak, D., & McGavern, D. B. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb1817 · Cited by 157
Dunning, J. W., Blankley, S., Hoang, L. T., Cox, M. J., Graham, C. M., James, P. L., Bloom, C. I., Chaussabel, D., Banchereau, J., Brett, S. J., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0111-5 · Cited by 157
Self-citationCytokine and lipid mediator networks in tuberculosis
Mayer-Barber, K. D., & Sher, A. (2015) · Immunological Reviews · doi:10.1111/imr.12249 · Cited by 158
Self-citationMolecular basis of mycobacterial survival in macrophages
Awuh, J. A., & Flo, T. H. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2422-8 · Cited by 160
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies
Market, M., Angka, L., Martel, A. B., Bastin, D. J., Olanubi, O., Tennakoon, G., Boucher, D. M., Ng, J., Ardolino, M., & Auer, R. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01512 · Cited by 158
The Signaling Pathways Regulating NLRP3 Inflammasome Activation
Chen, M.-Y., Ye, X.-J., He, X.-H., & Ouyang, D.-Y. (2021) · Inflammation · doi:10.1007/s10753-021-01439-6 · Cited by 154
Mitochondrial cristae architecture protects against mtDNA release and inflammation
He, B., Yu, H., Liu, S., Wan, H., Fu, S., Liu, S., Yang, J. J., Zhang, Z., Huang, H., Li, Q., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111774 · Cited by 157
Adaptive Immune Responses and Immunity to SARS-CoV-2
Primorac, D., Vrdoljak, K., Brlek, P., Pavelić, E., Molnar, V., Matišić, V., Ivkošić, I. E., & Parčina, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848582 · Cited by 162
Sodium in the microenvironment regulates immune responses and tissue homeostasis
Müller, D. N., Wilck, N., Haase, S., Kleinewietfeld, M., & Linker, R. A. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0113-4 · Cited by 149
The JAK-STAT pathway: from structural biology to cytokine engineering
Lv, Y., Qi, J., Babon, J. J., Cao, L., Fan, G.-H., Lang, J., Zhang, J., Mi, P., Kobe, B., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01934-w · Cited by 157
Lessons in self-defence: inhibition of virus entry by intrinsic immunity
Majdoul, S., & Compton, A. A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00626-8 · Cited by 152
Early cellular mechanisms of type I interferon-driven susceptibility to tuberculosis
Kotov, D. I., Lee, O. V., Fattinger, S. A., Langner, C. A., Guillen, J. V., Peters, J. M., Moon, A., Burd, E. M., Witt, K. C., Stetson, D. B., et al. (2023) · Cell · doi:10.1016/j.cell.2023.11.002 · Cited by 146
The role of respiratory epithelium in host defence against influenza virus infection
Denney, L., & Ho, L. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.08.004 · Cited by 154
The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections
Hsu, R., Yu, W.-C., Peng, G.-R., Ye, C.-H., Hu, S., Chong, P. C. T., Yap, K. Y., Lee, J. Y. C., Lin, W., & Yu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832394 · Cited by 148
Chen, J., Wang, T., Li, X., Gao, L., Wang, K., Cheng, M., Zeng, Z., Chen, L., Shen, Y., & Wen, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01881-6 · Cited by 143
The Role of IL-10 in Malaria: A Double Edged Sword
Kumar, R., Ng, S. S., & Engwerda, C. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00229 · Cited by 141
LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity
Liu, W., Wang, Z., Liu, L., Yang, Z., Liu, S., Ma, Z., Liu, Y., Ma, Y., Zhang, L., Zhang, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003932117 · Cited by 142
Systemic Immunometabolism: Challenges and Opportunities
Lercher, A., Baazim, H., & Bergthaler, A. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.012 · Cited by 144
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Potential Novel Role of COVID-19 in Alzheimer’s Disease and Preventative Mitigation Strategies
Naughton, S. X., Raval, U., & Pasinetti, G. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200537 · Cited by 139
Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection
Munnur, D., Teo, Q. W., Eggermont, D., Lee, H. H. Y., Théry, F., Ho, J., van Leur, S. W., Ng, W. W., Siu, L. Y.-L., Beling, A., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01035-8 · Cited by 139
Regulation of IRF3 activation in human antiviral signaling pathways
Hamrashdi, M. A., & Brady, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115026 · Cited by 137
Holíček, P., Guilbaud, E., Klapp, V., Truxová, I., Špíšek, R., Galluzzi, L., & Fucikova, J. P. (2023) · Immunological Reviews · doi:10.1111/imr.13272 · Cited by 143
Chitosan Immunomodulatory Properties: Perspectives on the Impact of Structural Properties and Dosage
Fong, D. W. F., & Hoemann, C. D. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0064 · Cited by 136
Pathogenesis and virulence of flavivirus infections
van Leur, S. W., Heunis, T. D. J., Munnur, D., & Sanyal, S. (2021) · Virulence · doi:10.1080/21505594.2021.1996059 · Cited by 135
Effects of Interferons and Viruses on Metabolism
Fritsch, S. D., & Weichhart, T. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00630 · Cited by 136
Modulation of Macrophage Immunometabolism: A New Approach to Fight Infections
Gauthier, T., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.780839 · Cited by 137
Li, H., Wang, Y., Zhang, J., Li, X., Wang, J., Yi, S., Zhu, W., Xu, Y., & Li, J. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2022.134325 · Cited by 134
Virus Control of Cell Metabolism for Replication and Evasion of Host Immune Responses
Moreno‐Altamirano, M. M. B., Kolstoe, S. E., & Sánchez-García, F. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00095 · Cited by 136
COVID-19 and MS disease-modifying therapies
Berger, J. R., Brandstadter, R., & Bar‐Or, A. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000761 · Cited by 132
SARS-CoV-2 in immunocompromised individuals
DeWolf, S., Laracy, J. C., Perales, M., Kamboj, M., van den Brink, M. R. M., & Vardhana, S. A. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.006 · Cited by 143
Interferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
Type I interferons in host defence and inflammatory diseases
Crow, M. K., & Rönnblom, L. (2019) · Lupus Science & Medicine · doi:10.1136/lupus-2019-000336 · Cited by 134
The TRIMendous Role of TRIMs in Virus–Host Interactions
van Tol, S., Hage, A., Giraldo, M. I., Bharaj, P., & Rajsbaum, R. (2017) · Vaccines · doi:10.3390/vaccines5030023 · Cited by 133
Hertzog, J., Dias, A. G., Rigby, R. E., Donald, C. L., Mayer, A., Sezgin, E., Song, C., Jin, B., Hublitz, P., Eggeling, C., et al. (2018) · European Journal of Immunology · doi:10.1002/eji.201847483 · Cited by 129
Grabowska, J. A., Venegas, M. L., Affandi, A. J., & den Haan, J. M. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02472 · Cited by 136
Shemesh, M., Aktepe, T. E., Deerain, J. M., McAuley, J., Audsley, M. D., David, C. T., Purcell, D. F. J., Urin, V., Hartmann, R., Moseley, G. W., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009800 · Cited by 137
A humanized mouse model of chronic COVID-19
Sefik, E., Israelow, B., Mirza, H., Zhao, J., Qu, R., Kaffe, E., Song, E., Halene, S., Meffre, E., Kluger, Y., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01155-4 · Cited by 136
Schmid‐Hempel, P. (2021) · doi:10.1093/oso/9780198832140.001.0001 · Cited by 137
Andrade, W. A., Firon, A., Schmidt, T., Hornung, V., Fitzgerald, K. A., Kurt‐Jones, E. A., Trieu‐Cuot, P., Golenbock, D. T., & Kaminski, P. A. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.06.003 · Cited by 132
Interferon Lambda Genetics and Biology in Regulation of Viral Control
Hemann, E. A., Gale, M., & Savan, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01707 · Cited by 135
Skin manifestations of COVID‐19 in children: Part 1
Martínez, D. A., Fortina, A. B., Bodemer, C., Bonifazi, E., Chiriac, A. E., Colmenero, I., Diociaiuti, A., El‐Hachem, M., Fertitta, L., Gysel, D. V., et al. (2020) · Clinical and Experimental Dermatology · doi:10.1111/ced.14481 · Cited by 129
Kowalzik, F., Schreiner, D., Jensen, C., Teschner, D., Gehring, S., & Zepp, F. (2021) · Vaccines · doi:10.3390/vaccines9040390 · Cited by 133
Differential roles of interferons in innate responses to mucosal viral infections
Walker, F. C., Sridhar, P., & Baldridge, M. T. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.09.003 · Cited by 130
Sanjuán, M. A. F., Sagar, D., & Kolbeck, R. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.007 · Cited by 129
Gröschel, M. I., Sayes, F., Shin, S. J., Frigui, W., Pawlik, A., Orgeur, M., Canetti, R., Honoré, N., Simeone, R., van der Werf, T. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.057 · Cited by 125
Type I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124
Singhania, A., Wilkinson, R. J., Rodrigue, M., Haldar, P., & O’Garra, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0225-9 · Cited by 126
Self-citationADAR1 and ZBP1 in innate immunity, cell death, and disease
Karki, R., & Kanneganti, T. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.01.001 · Cited by 122
Innate immunity, cytokine storm, and inflammatory cell death in COVID-19
Karki, R., & Kanneganti, T. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03767-z · Cited by 131
T Cell–Derived IL-10 Impairs Host Resistance to Mycobacterium tuberculosis Infection
Moreira-Teixeira, L., Redford, P. S., Stavropoulos, E., Ghilardi, N., Maynard, C. L., Weaver, C. T., do Rosário, A. P. F., Wu, X., Langhorne, J., & O’Garra, A. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601340 · Cited by 122
Self-citationLercher, A., Bhattacharya, A., Popa, A., Caldera, M., Schlapansky, M. F., Baazim, H., Agerer, B., Gürtl, B., Kosack, L., Májek, P., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.10.014 · Cited by 124
Bengtsson, A. A., & Rönnblom, L. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2017.10.003 · Cited by 121
Mycobacterium tuberculosis –induced IFN-β production requires cytosolic DNA and RNA sensing pathways
Cheng, Y., & Schorey, J. S. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180508 · Cited by 122
Karnell, J. L., Wu, Y., Mittereder, N., Smith, M. A., Gunsior, M., Yan, L., Casey, K. A., Hénault, J., Riggs, J. M., Nicholson, S. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf8442 · Cited by 121
Obesity-Related Microenvironment Promotes Emergence of Virulent Influenza Virus Strains
Honce, R., Karlsson, E. A., Wohlgemuth, N., Estrada, L. D., Meliopoulos, V., Yao, J., & Schultz‐Cherry, S. (2020) · mBio · doi:10.1128/mbio.03341-19 · Cited by 121
lncRNAs regulate the innate immune response to viral infection
Ouyang, M. J., Hu, J., & Chen, J. (2015) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1321 · Cited by 117
Type I interferons in bacterial infections: A balancing act
Kovarik, P., Castiglia, V., Ivin, M., & Ebner, F. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00652 · Cited by 117
Negative regulation of type I IFN signaling
Arimoto, K.-I., Miyauchi, S., Stoner, S. A., Fan, J.-B., & Zhang, D.-E. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0817-342r · Cited by 117
Biolatti, M., Dell’Oste, V., Pautasso, S., Gugliesi, F., von Einem, J., Krapp, C., Jakobsen, M. R., Borgogna, C., Gariglio, M., Andrea, M. D., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01774-17 · Cited by 122
Chen, S., Bonifati, S., Qin, Z., Gelais, C. S., Kodigepalli, K. M., Barrett, B. S., Kim, S. H., Antonucci, J. M., Ladner, K. J., Buzovetsky, O., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801213115 · Cited by 117
Duncan, C. J. A., Thompson, B. J., Chen, R., Rice, G., Gothe, F., Young, D. F., Lovell, S. C., Shuttleworth, V. G., Brocklebank, V., Corner, B. M., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aav7501 · Cited by 115
Gangaplara, A., Martens, C., Dahlstrom, E. W., Metidji, A., Gokhale, A. S., Glass, D. D., Lopez-Ocasio, M. D., Baur, R., Kanakabandi, K., Porcella, S. F., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006985 · Cited by 114
Penn, B. H., Netter, Z., Johnson, J. R., Dollen, J. V., Jang, G. Μ., Johnson, T. L., Ohol, Y. M., Maher, C., Bell, S. L., Geiger, K. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.010 · Cited by 118
Ghosh, A., Shao, L., Sampath, P., Zhao, B., Patel, N. V., Zhu, J., Behl, B., Parise, R. A., Beumer, J. H., O’Sullivan, R. J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.013 · Cited by 118
Xue, Y., Liu, C., Andrews, G., Wang, J., & Ge, Y. (2022) · Nano Convergence · doi:10.1186/s40580-022-00307-9 · Cited by 114
Krakauer, T. (2019) · Mediators of Inflammation · doi:10.1155/2019/2471215 · Cited by 115
Lanosterol Modulates TLR4-Mediated Innate Immune Responses in Macrophages
Araldi, E., Fernández‐Fuertes, M., Canfrán‐Duque, A., Tang, W., Cline, G. W., Madrigal‐Matute, J., Pober, J. S., Lasunción, M. A., Wu, D., Fernandez-Hernando, C. F., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.093 · Cited by 115
Roles and regulation of microglia activity in multiple sclerosis: insights from animal models
Distéfano‐Gagné, F., Bitarafan, S., Lacroix, S., & Gosselin, D. (2023) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00709-6 · Cited by 115
Macrophage Polarization in Virus-Host Interactions
Miller, Y. S. L. C. (2015) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000311 · Cited by 115
Metadata
- Authors
- McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- National Institutes of Health (US)
- National Institute for Medical Research (GB)
- Venue
- Nature Reviews Immunology
- Published
- 2015-01-23
- Volume
- 15
- Issue
- 2
- Pages
- 87-103
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7162685
- OpenAlex
- W2091129202
- Cited by
- 2,780
- References
- 238
- Citations by year
- 2026: 263 · 2025: 333 · 2024: 364 · 2023: 330 · 2022: 330 · 2021: 307 · 2020: 194 · 2019: 160 · 2018: 166 · 2017: 169 · 2016: 119 · 2015: 44
- FWCI
- 15.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust (FC001126)
- Francis Crick Institute (10206, 10126)
- Cancer Research UK (FC001126)
- National Institutes of Health
- Medical Research Council (U117597139, U117565642)
- National Institute of Allergy and Infectious Diseases
- FP7 Ideas: European Research Council (294682)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- type I interferon, innate immunity, viral infection, bacterial infection, parasitic infection, fungal infection, immunopathology, influenza virus, lymphocytic choriomeningitis virus, chronic viral infection, immunosuppression, B cell response, macrophage activation, Listeria monocytogenes, Mycobacterium tuberculosis, prostaglandin E2, interleukin-1, host defense
- MeSH terms
- Animals, Bacterial Infections, Communicable Diseases, Humans, Interferon Type I, Mycoses, Parasitic Diseases, Virus Diseases, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
